1. Home
  2. AIRI vs TCRX Comparison

AIRI vs TCRX Comparison

Compare AIRI & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air Industries Group

AIRI

Air Industries Group

N/A

Current Price

$2.65

Market Cap

12.3M

Sector

Industrials

ML Signal

N/A

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

N/A

Current Price

$0.16

Market Cap

11.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AIRI
TCRX
Founded
1979
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3M
11.8M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
AIRI
TCRX
Price
$2.65
$0.16
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
★ $1.00
AVG Volume (30 Days)
34.4K
★ 476.9K
Earning Date
11-09-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 24.39
12.28
EPS
★ N/A
N/A
Revenue
★ $47,921,000.00
$10,325,000.00
Revenue This Year
$4.34
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 266.65
52 Week Low
$2.30
$0.17
52 Week High
$3.95
$1.47

Technical Indicators

Market Signals
Indicator
AIRI
TCRX
Relative Strength Index (RSI) 48.14 31.96
Support Level $2.50 N/A
Resistance Level $2.75 $0.21
Average True Range (ATR) 0.23 0.02
MACD 0.02 0.01
Stochastic Oscillator 50.53 8.01

Price Performance

Historical Comparison
AIRI
TCRX

About AIRI Air Industries Group

Air Industries Group is an aerospace and defense company. Its manufacturers of precision components and assemblies for large aerospace and defense prime contractors. The company products include landing gears, flight controls, engine mounts and components for aircraft jet engines, ground turbines and other complex machines. The ultimate end-user of products is the U.S. Government, international governments, and commercial global airlines.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: